Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Therapy monitoring
G. Matzander, J. Klingelhöfer, Ingo Wittich, Dirk Sander, B. Conrad, Ch. Kessler, Milka Maravic, Michael Müller, D. Dorndorf, D. Kömpf, A Delcker, Dagmar Timmann, Hans‐Christoph Diener, Manfred Kaps, S. Trittmacher, G. Seidel, Maxwell S. Damian, Andreas Thie, M. Carvajal-Lizano, Jacob Steinmetz, F. Zanella, Klaus Spitzer, H. Zeumer, Klaus Kunze, F. Ries, E. Keller, F. Grünwald, C. Honisch, F. Rosanowski, Martin Kurthen, L. Solymosi, Cornelius Weiller, Karl Friston, R. S. J. Frackowiak, Lutz Harms, S. Enchtuja, Gerald W. Timm, R. Zschenderlein, Bernhard Schnackenburg, Stephen D. Walter, P. H. Kraus, T. Fritsch, P. Tran-Gia, H. Przuntek, Klaus Spitzer, Klaus Kunze, Andreas Thie, Günter Krämer, Study Group, R. Lindemuth, U. Mielke, Wolfgang H. Jost, I. Maurer, A. Marian, W. Kühn, Max J. Hilz, U. Faatz, Matthew J. Weis, F. Erbguth, B. Neundörfer, K. Maier-Hauff, G. Barzen, H. Gottschalk, Jan Schwarz, Karen Finger Tatsch, Georgianne L. Arnold, C. Trenwalder, Jennifer S. Scherer, C. M. Kirsch, Oertel Wh, Th. Wißmeyer, P.-J. Hülser, T. Kutter, L. Kinzl, H. Baas, L. Demisch, Signe Harder, P.-A. Fischer, J. Dressnandt, A. Konstanzer, Ulrich Bogdahn, A.E.J. de Jager, Joshua Richter, A. Krone, A Dekant, Amanda A. Beck, B. Pfeufer, Herwig Strik, P. Krauseneck, Erik A. Richter, B. Zahner, Hermann Stefan, H. Feistel, Michael E. Harrer, J. Treib, Matthias Stoll, A. Haaß, V. Jost, Hans-Christean Nahser, D. Kühne (1992). Therapy monitoringDOI: https://doi.org/10.1007/978-3-662-39699-5_3,
Chapter in a book300 days agoCarfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
Katja Weisel, Meletios A Dimopoulos, Meral Beksaç, Xavier Leleu, Joshua Richter, Bart Heeg, Sachin Patel, István Májer, Ian McFadden, Joseph Mıkhael (2024). Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison. , 65(4), DOI: https://doi.org/10.1080/10428194.2023.2300051.
Article33 days agoCarfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
Katja Weisel, Meletios A Dimopoulos, Meral Beksaç, Xavier Leleu, Joshua Richter, Bart Heeg, Sachin Patel, István Májer, Ian McFadden, Joseph Mıkhael (2024). Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison. , 65(4), DOI: https://doi.org/10.1080/10428194.2023.2300051.
Article33 days agoManagement of Patients with Difficult-To-Treat Multiple Myeloma
Joshua Richter, Karthik Ramasamy, Leo Rasche, Joan Bladé, Sonja Zweegman, Faith E. Davies, Meletios A Dimopoulos (2021). Management of Patients with Difficult-To-Treat Multiple Myeloma. , 17(16), DOI: https://doi.org/10.2217/fon-2020-1280.
Article33 days agoQuality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Gabriel Tremblay, Patrick Daniele, Janis L. Breeze, Lingling Li, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay K. Nooka, Dan T. Vogl, Maria Gavriatopoulou, Meletios A Dimopoulos, Paul G. Richardson, Noa Biran, David S. Siegel, Philip Vlummens, Chantal Doyen, Thierry Façon, Mohamad Mohty, Nathalie Meuleman, Moshe Levy, Luciano J. Costa, James E. Hoffman, Michel Delforge, David Kaminetzky, Katja Weisel, Marc S. Raab, David Dingli, Sascha A. Tuchman, Laurent Frenzel, Ravi Vij, Gary J. Schiller, Philippe Moreau, Joshua Richter, Martin Schreder, Klaus Podar, Terri L. Parker, Robert F. Cornell, Lionel Karlin, Sylvain Choquet, Sundar Jagannath (2021). Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. , 21(1), DOI: https://doi.org/10.1186/s12885-021-08453-9.
Article33 days ago